ML20137R251

Positive Ballot Re SECY-84-485, Proposed Rev of 10CFR35, `Medical Use of Byproduct Matl. Comments Encl

ML20137R251
Person / Time
Issue date:	05/05/1985
From:	Palladino N NRC COMMISSION (OCM)
To:	Chilk S NRC OFFICE OF THE SECRETARY (SECY)
Shared Package
ML20136D915	List: ML20136D909 ML20136E266 ML20136E272 ML20136E278 ML20136E295 ML20136E318 ML20136E323 ML20136E492 ML20136E705 ML20136E879 ML20136F099 ML20136F109 ML20136F154 ML20137Q526 ML20137Q531 ML20137Q538 ML20137Q545 ML20137Q557 ML20137Q566 ML20137Q572 ML20137Q579 ML20137Q585 ML20137Q596 ML20137Q605 ML20137Q612 ML20137Q619 ML20137Q628 ML20137Q633 ML20137Q639 ML20137Q644 ML20137Q650 ML20137Q655 ML20137Q660 ML20137Q668 ML20137Q671 ML20137Q676 ML20137Q682 ML20137Q686 ML20137Q688 ML20137Q690 ML20137Q692 ML20137Q695 ML20137Q697 ML20137Q705 ML20137Q710 ML20137Q715 ML20137Q719 ML20137Q721 ML20137Q724 ML20137Q726 ... further results
References
FRN-50FR30616, RULE-PR-35 AA73-1, NUDOCS 8509230446
Download: ML20137R251 (2)

Text

McE4.y

~

N 0"T ~

T'I 0 N V0TE cc gg,7 cgs JRoe O

RESPONSE SHEET WKerr MI

~

T0:

SAMUEL J. CHILK, SECRETARY OF THE COMMISSION h

FROM:

CHAIRMAN PALLADINO VS&

SUBJECT:

SECY-84-485 - PROPOSED REVISION OF 10 CFR PART 35 c-

~

" MEDICAL USE OF BYPRODUCT MATERIAL" APPROVED

' *x '

DIS PPROVED ABSTAIN NOT PARTICIPATING REQUEST DISCUSSION COMMENTS:

p (See attached comments)

L) nNu)

~ ',

GNAIURE

'~~'

Sog92gg446e50w6

,,,f, y 35 50FR30616 PDR i

O SECRETARIAT NOTE:

PLEASE ALSO RESPOND TO-AND/OR COMMENT ON OGC/0PE MEMORANDUM IF ONE HAS BEEN ISSUED ON THIS PAPER.

NRC-SECY FORM DEC. 80

I CHAIRMAN PALLADIN0'S COMMENTS ON SECY-84-485 em

, U The comments, recommendations and modifications proposed by Commissioners Zech, Bernthal and Asselstine have merit and are worthy of further consideration.

However, I also believe that the proposed revision to 10 CFR 35 is a marked improvement and, as such, should be issued for comment.

I believe that the issues raised can, and would better, be addressed by the staff during the comment period.

Therefore, in the interest of avoiding delay, I approve the issuance of the proposed rule as is.

In the interim until comments on the proposed rule are received and evaluated, staff should continue to work in three areas:

(1)

The basis for the need to exempt minor license requirements from NRC review, and the criteria for defining minor requirements, should be clarified; (2)

The staff should meet with the Advisory Committee on Medical Uses of Byproduct Isotopes and determine what level of physician training is appropriate; and (3)

The staff should further investigate the subject of medical misadministration enforcement, and propose a course of action to address this subject as a second

(])

and separate proceeding.